RPE65 and inherited retinal dystrophy: <h4>Purpose</h4>Voretigene neparvovec (VN), developed for the treatment of inherited retinal dystrophy (IRD) associated with confirmed biallelic <i>RPE65</i> mutations (<i>RPE65-</i>IRD), is the first approved retinal gene therapy.